The availability of radioisotopes for sentinel lymph node biopsy (SLNB) in breast carcinoma is limited in low- and middle-income countries and thus the need for other reliable tracers exists. We aimed to validate the effectiveness of fluorescein sodium (FS) together with methylene blue dye (MBD) for patients with node-negative early breast carcinoma in a prospective cross-sectional study. Patients underwent SLNB using FS and MBD followed by axillary dissection to validate results. Sentinel lymph node (SLN) identification rate and false negative rate were assessed for all three tracers/combinations (MBD, FS, and MBD + FS). We concluded that SLNB using a combination of FS and MBD has an acceptable rate of SLN identification but the addition of FS provided no additional benefit.
PurushothamADUpponiSKlevesathMB, et al.Morbidity after sentinel lymph node biopsy in primary breast cancer: Results from a randomized controlled trial. J Clin Oncol2005; 23: 4312–4321.
2.
ManselREFallowfieldLKissinM, et al.Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC trial. J Natl Cancer Inst2006; 98: 599–609.
3.
ZavagnoGDe SalvoGLScalcoG, et al.A randomized clinical trial on sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer: Results of the Sentinella/GIVOM trial. Ann Surg2008; 247: 207–213.
4.
CanaveseGCatturichAVecchioC, et al.Sentinel node biopsy compared with complete axillary dissection for staging early breast cancer with clinically negative lymph nodes: Results of randomized trial. Ann Oncol2009; 20: 1001–1007.
5.
GillG, SNAC Trial Group of the Royal Australasian College of Surgeons (RACS) and NHMRC Clinical Trials Centre. Sentinel-lymph-node-based management or routine axillary clearance? One-year outcomes of sentinel node biopsy versus axillary clearance (SNAC): A randomized controlled surgical trial. Ann Surg Oncol2009; 16: 266–275.
6.
KragDNAndersonSJJulianTB, et al.Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: Overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol2010; 11: 927–933.
7.
VeronesiUVialeGPaganelliG, et al.Sentinel lymph node biopsy in breast cancer: Ten-year results of a randomized controlled study. Ann Surg2010; 251: 595–600.
8.
SchwartzGFD’UgoDMRosenbergAL. Extent of axillary dissection preceding irradiation for carcinoma of the breast. Arch Surg 19601986; 121: 1395–1398.
9.
TandonP. Regulatory requirements for designing PET-CT facility in India. Indian J Nucl Med2010; 25: 39–43.
10.
ChangYWLeeHYLeeCM, et al.Sentinel lymph node detection using fluorescein and blue light-emitting diodes in patients with breast carcinoma: A single-center prospective study. Asian J Surg2020; 43: 220–226.
11.
LiLGaoNYangAQ, et al.Application of fluorescein combined with methylene blue in sentinel lymph node biopsy of breast cancer. Sci Rep2021; 11: 12119.
12.
ValiveruRCAgarwalGAgrawalV, et al.Low-cost fluorescein as an alternative to radio-colloid for sentinel lymph node biopsy – a prospective validation study in early breast cancer. World J Surg2020; 44: 3417–3422.
13.
KhadkaSSureshJPremA, et al.Sentinel node mapping in early breast cancer: a randomized comparison of fluorescein guided All India Institute of Medical Sciences, Anurag’s technique with Technetium-99 m Sulfur colloid plus methylene blue. Indian J Nucl Med2022; 37: 236–244.
14.
ChavdaJMishraASilodiaA, et al.Validation sentinel lymph node biopsy study in cN0 axilla using low-cost dual dye technique: Potential solution for resource poor settings. Breast Cancer Res Treat2022; 193: 105–110.
15.
KerseyTWVan EykJLanninDR, et al.Comparison of intradermal and subcutaneous injections in lymphatic mapping. J Surg Res2001; 96: 255–259.
16.
YadavSKBharathSSharmaD, et al.A systematic review and meta-analysis of diagnostic performance of fluorescein-guided sentinel lymph node biopsy in early breast cancer. Breast Cancer Res Treat2024; 206: 19–30.
